| Aggressive pituitary tumours and pituitary carcinomas G Raverot, MD Ilie, H Lasolle, V Amodru, J Trouillas, F Castinetti, T Brue Nature Reviews Endocrinology 17 (11), 671-684, 2021 | 92 | 2021 |
| Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature C Duhamel, MD Ilie, H Salle, AS Nassouri, S Gaillard, E Deluche, ... Journal of Personalized Medicine 10 (3), 88, 2020 | 66 | 2020 |
| The microenvironment of pituitary tumors—biological and therapeutic implications MD Ilie, A Vasiljevic, G Raverot, P Bertolino Cancers 11 (10), 1605, 2019 | 55 | 2019 |
| Emerging and novel treatments for pituitary tumors MD Ilie, H Lasolle, G Raverot Journal of clinical medicine 8 (8), 1107, 2019 | 48 | 2019 |
| Aggressive Pituitary Adenomas and Carcinomas MD Ilie, E Jouanneau, G Raverot Endocrinology and Metabolism Clinics of North America 49 (3), 505-515, 2020 | 36 | 2020 |
| Immune Landscape of Pituitary Neuroendocrine Tumours Reveals Association between Macrophages and Gonadotroph-Tumour Invasion M Principe, M Chanal, MD Ilie, A Ziverec, A Vasiljevic, E Jouanneau, ... The Journal of Clinical Endocrinology & Metabolism, dgaa520, 2020 | 34* | 2020 |
| Aggressive prolactinomas: how to manage? H Lasolle, MD Ilie, G Raverot Pituitary 23, 70-77, 2020 | 32 | 2020 |
| Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and … C Briet, MD Ilie, E Kuhn, L Maione, S Brailly-Tabard, S Salenave, ... Endocrine 63, 348-360, 2019 | 32 | 2019 |
| Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study MD Ilie, C Villa, T Cuny, C Cortet, G Assie, B Baussart, M Cancel, ... European journal of endocrinology 187 (5), 685-696, 2022 | 28 | 2022 |
| Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review MD Ilie, A Vasiljevic, E Jouanneau, G Raverot Endocrine-related cancer 29 (7), 415-426, 2022 | 25 | 2022 |
| Aggressive corticotroph tumors and carcinomas H Lasolle, A Vasiljevic, E Jouanneau, MD Ilie, G Raverot Journal of Neuroendocrinology, 2022 | 22 | 2022 |
| Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas MD Ilie, A Vasiljevic, P Bertolino, G Raverot Endocrine reviews 44 (2), 297-311, 2023 | 20 | 2023 |
| Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy MD Ilie, A Vasiljevic, C Louvet, E Jouanneau, G Raverot Cancers 12 (4), 1012, 2020 | 20 | 2020 |
| Treatment options for gonadotroph tumors: current state and perspectives MD Ilie, G Raverot The Journal of Clinical Endocrinology & Metabolism, dgaa497, 2020 | 19 | 2020 |
| Immunotherapy in pituitary carcinomas and aggressive pituitary tumors G Raverot, MD Ilie Best Practice & Research Clinical Endocrinology & Metabolism 36 (6), 101712, 2022 | 14 | 2022 |
| Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study MD Ilie, A Tabarin, A Vasiljevic, JF Bonneville, L Moreau-Grangé, ... The Journal of Clinical Endocrinology & Metabolism 107 (11), 2982-2991, 2022 | 14 | 2022 |
| Cabergoline in severe ectopic or occult Cushing’s syndrome MD Ilie, V Raverot, F Tronc, A Vasiljevic, F Borson-Chazot, G Raverot Eur J Endocrinol 181 (1), K1-K9, 2019 | 10 | 2019 |
| Intratumoural spatial distribution of S100B+ folliculostellate cells is associated with proliferation and expression of FSH and ERα in gonadotroph tumours MD Ilie, A Vasiljevic, M Chanal, N Gadot, L Chinezu, E Jouanneau, ... Acta Neuropathologica Communications 10 (1), 18, 2022 | 6 | 2022 |
| Therapeutic targeting of the pituitary tumor microenvironment MD Ilie, D De Alcubierre, AL Carretti, E Jouanneau, G Raverot Pharmacology & Therapeutics, 108506, 2023 | 4 | 2023 |
| Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review P Raymond, G Raverot, MD Ilie Endocrine-Related Cancer 30 (5), 2023 | 4 | 2023 |
